ESR1 and breast carcinoma: STP analysis enabled calculation of an AR over ER pathway activity ratio instead of the AR over ER protein expression ratio, revealing a relatively low ratio in luminal A/B and a high ratio in higher grade HER2 and basal breast cancer subtypes.